Related Experiment Video
Updated: Apr 5, 2026
08:03
Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
Published on: June 6, 2018
15.4K
Does prostaglandin E1 therapy modify the intracavernous musculature?
E Wespes1, A A Sattar, J C Noël
1Department of Urology, Erasme Hospital, Université Libre de Bruxelles, Brussels.
The Journal of Urology
|January 27, 2000
Summary
Long-term intracavernous prostaglandin E1 (PGE1) treatment for erectile dysfunction showed no significant histological changes in penile smooth muscle. This study found PGE1 does not appear to alter intracavernous structures after extensive use.
Area of Science:
- Urology
- Andrology
- Histopathology
Background:
- Intracavernous prostaglandin E1 (PGE1) is a common treatment for erectile dysfunction.
- Long-term histological effects of PGE1 on penile smooth muscle are not well-documented.
Purpose of the Study:
- To evaluate histological changes in intracavernous smooth muscle following long-term PGE1 treatment in patients with erectile dysfunction.
Main Methods:
- Biopsies of corpora cavernosa were taken before and after PGE1 treatment in 10 patients over 3 years.
- Histological analysis included H&E staining and immunohistochemistry for actin.
- Computerized image analysis quantified smooth muscle percentage.
Main Results:
- Classic staining revealed no histological differences.
- A reduction in smooth muscle percentage was observed in 2 of 5 patients on the injection side.
- No differences were noted in the contralateral corpus cavernosum or in patients biopsied only post-treatment.
Conclusions:
- Intracavernous prostaglandin E1 treatment does not appear to cause significant long-term histological alterations to penile smooth muscle structures.
Related Concept Videos
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
2.6K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.6K
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
2.0K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
2.0K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
612
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
612
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.6K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.6K
01:17Male Sexual Response: Erection & Ejaculation
27.8K
Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
27.8K
01:21Intrauterine Drug Delivery Systems
130
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
130